Bioanalytical Systems Inc. (NASDAQ:BASI) announced that it will report financial results for the third quarter of fiscal 2015 ended June 30, 2015, prior to the market opening on Thursday, August 13, 2015. A conference call has been scheduled at 11:00 a.m. Eastern Daylight Time (EDT) to discuss the results. To participate in the call, dial (866) 865-2633. Bioanalytical Systems Inc. (NASDAQ:BASI) belongs to Services sector. Its net profit margin is 0.80% and weekly performance is 2.72%. On last trading day company shares ended up $1.51. Bioanalytical Systems Inc. (NASDAQ:BASI) distance from 50-day simple moving average (SMA50) is -19.84%.
CEMEX, S.A.B. de C.V. (NYSE:CX) announced that it has fully repaid the total amount outstanding of approximately U.S.$1.94 billion under the facilities agreement dated September 17, 2012, as amended from time to time (the “2012 Facilities Agreement”), with new funds from 17 financial institutions. These lenders have joined the credit agreement dated September 29, 2014, as amended (the “Credit Agreement”) under new tranches, allowing CEMEX to increase the average life of its syndicated bank debt to approximately 4 years. Other financial institutions may join the Credit Agreement in the following months. CEMEX, S.A.B. de C.V. (NYSE:CX) shares advanced 3.27% in last trading session and ended the day at $8.52. CX Gross Margin is 32.00% and its return on assets is -1.40%. CEMEX, S.A.B. de C.V. (NYSE:CX) quarterly performance is -15.89%.
Haverty Furniture Companies Inc. (NYSE:HVT) reports earnings per share of $0.21 for the second quarter and $0.48 for the first half of 2015 which are the same earnings per share results as the comparable periods in 2014. As previously announced, net sales increased 7.2% to $187.7 million. Comparable store sales were up 4.8%. Total written sales were up 5.0% and written comparable store sales were up 2.4%.Average written ticket was up 3.3% and sales of custom upholstery increased 10.2%. Gross profit margins were 53.4% versus 53.8% of sales, slightly better than our expectations. On 07 August, Haverty Furniture Companies Inc. (NYSE:HVT) shares advanced 0.32% and was closed at $22.14. HVT EPS growth in last 5 year was 29.90%. Haverty Furniture Companies Inc. (NYSE:HVT) year to date (YTD) performance is 1.32%.
The Allstate Corporation (NYSE:ALL) reported financial results for the second quarter of 2015. Allstate’s revenues were $9.0 billion in the second quarter of 2015, reflecting a 4.7% increase in insurance premium from the prior year quarter, which was partially offset by lower investment income and capital gains. Net income available to common shareholders was $326 million for the second quarter of 2015 and $974 million for the first six months of 2015. Operating income was $262 million, or $0.63 cents per share, in the second quarter of 2015, as lower auto insurance margins and seasonally high catastrophe losses resulted in a small underwriting loss. Operating income return on shareholders’ equity was 11.9% over the trailing twelve months. Book value per share in the second quarter of 2015 was comparable to the second quarter of 2014, reflecting the impact of dividends, share repurchases and a decline in unrealized gains on the investment portfolio. The Allstate Corporation (NYSE:ALL) ended the last trading day at $62.54. Company weekly volatility is calculated as 2.49% and price to cash ratio as 27.93. The Allstate Corporation (NYSE:ALL) showed a weekly performance of -9.30%.
Insmed Incorporated (NASDAQ:INSM) reported financial results for the second quarter and six months ended June 30, 2015. Global phase 3 study expanding. Patient enrollment is advancing in the company’s global phase 3 study of ARIKAYCE(TM) (liposomal amikacin for inhalation or LAI) in nontuberculous mycobacteria (NTM) lung disease (the “212” or CONVERT(TM) study). The company has secured health authority clearance in 10 countries with CONVERT study sites. In addition to the U.S., patient recruitment is underway in Australia, Canada, Europe, and New Zealand. With strong interest among clinical investigators, Insmed is expanding the total number of CONVERT clinical sites to more than 100. Insmed Incorporated (NASDAQ:INSM) shares advanced 0.49% in last trading session and ended the day at $26.88. Its return on assets is -44.80%. Insmed Incorporated (NASDAQ:INSM) quarterly performance is 20.65%.